News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Mar 17, 2022
Clover's COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a BoosterFeb 24, 2022
Clover Selected for Inclusion on the Hang Seng Composite IndexFeb 14, 2022
Clover Provides Corporate Update and 2022 PrioritiesFeb 01, 2022
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and DevelopmentJan 21, 2022
Clover's Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The LancetJan 05, 2022
Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRAJan 05, 2022
Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong ShanghaiDec 09, 2021
Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal CarcinomatosisDec 07, 2021
Clover Signs COVID-19 Vaccine Supply Agreement with UNICEFNov 26, 2021
Clover's COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
